🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526076-23-00
Authorised Phase I

A Phase 1, non-randomized, fixed-sequence, multiple-dose study investigating the drug drug interaction potential and QTc effects of fosmanogepix in healthy adult subjects.

2026-526076-23-00 · tracked via the Priya Life Science EU tracker
Sponsor
Basilea Pharmaceutica International AG Allschwil
Sponsor type
Pharmaceutical company
Therapeutic area
Not possible to specify
Decision date
21/09/2026
Enrollment target
42
Sites
Netherlands

Condition studied

Invasive fungal infections (IFIs)

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526076-23-00 on CTIS ↗ ← All trials in the EU